GTBP GT Biopharma Inc
Price (delayed)
$2.18
Market cap
$4.87M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$7.65
Enterprise value
-$4.38M
GT Biopharma, Inc. is a clinical stage biopharmaceutical company focused on the development and commercialization of immuno-oncology therapeutic products based our proprietary TriKE™ NK cell engager platform. Our TriKE™ platform
Highlights
The debt has shrunk by 100% QoQ and by 100% YoY
GT Biopharma's equity has shrunk by 53% YoY but it has increased by 3.7% QoQ
GTBP's EPS is up by 44% year-on-year but it is down by 10% since the previous quarter
Key stats
What are the main financial stats of GTBP
Market
Valuations
Earnings
Shares outstanding
2.23M
Market cap
$4.87M
Enterprise value
-$4.38M
Price to earnings (P/E)
N/A
Price to book (P/B)
0.56
Price to sales (P/S)
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Revenue
$0
EBIT
-$11.35M
EBITDA
-$11.35M
Free cash flow
-$11.71M
Per share
Balance sheet
Liquidity
EPS
-$7.65
Free cash flow per share
-$6.84
Book value per share
$3.89
Revenue per share
$0
TBVPS
$5.41
Total assets
$9.27M
Total liabilities
$3.76M
Debt
$0
Equity
$5.51M
Working capital
$5.51M
Debt to equity
0
Current ratio
2.47
Quick ratio
2.46
Net debt/EBITDA
0.81
Margins
Efficiency
Dividend
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Return on assets
-91.9%
Return on equity
-160.5%
Return on invested capital
-311.1%
Return on capital employed
-206.1%
Return on sales
N/A
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
GTBP stock price
How has the GT Biopharma stock price performed over time
Intraday
0%
1 week
0.46%
1 month
-3.11%
1 year
-74.05%
YTD
-71.5%
QTD
-22.97%
Financial performance
How have GT Biopharma's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$13.29M
Net income
-$11.35M
Gross margin
N/A
Net margin
N/A
GTBP's operating income is up by 34% year-on-year but it is down by 2.2% since the previous quarter
The company's net income rose by 23% YoY but it fell by 18% QoQ
Growth
What is GT Biopharma's growth rate over time
Valuation
What is GT Biopharma stock price valuation
P/E
N/A
P/B
0.56
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
GTBP's EPS is up by 44% year-on-year but it is down by 10% since the previous quarter
GT Biopharma's equity has shrunk by 53% YoY but it has increased by 3.7% QoQ
The price to book (P/B) is 49% lower than the last 4 quarters average of 1.1
Efficiency
How efficient is GT Biopharma business performance
The ROIC has plunged by 141% YoY and by 134% from the previous quarter
GTBP's ROE is down by 44% since the previous quarter and by 43% year-on-year
The company's return on assets fell by 39% QoQ and by 19% YoY
Dividends
What is GTBP's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for GTBP.
Financial health
How did GT Biopharma financials performed over time
GT Biopharma's total assets is 147% more than its total liabilities
GT Biopharma's total assets has decreased by 49% YoY and by 7% from the previous quarter
The total liabilities has contracted by 41% YoY and by 18% from the previous quarter
The debt is 100% lower than the equity
The debt has shrunk by 100% QoQ and by 100% YoY
The company's debt to equity has shrunk by 100% QoQ and by 100% YoY
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.